We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the ...

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects a recovery of Wegovy weight-loss drug ...

Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) ...

Novo Nordisk says it's now cutting its annual outlook - seeing sales growth, at constant exchange rates, between 13% and 21%, vs. its previous forecast of 16% to 24%, and operating profit growth ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...